Other
Tislelizumab
0
Pipeline Programs↗
14
Active Trials↗
1
Companies Involved↗
Tislelizumab is an early-stage landscape with 0 programs across 1 company. The most active players are BeiGene.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
32
clinical trials
Unknown status14 · 44%
Recruiting8 · 25%
Not yet recruiting4 · 13%
Completed3 · 9%
Active, not recruiting2 · 6%
Withdrawn1 · 3%
Clinical Trials
Trial Activity
32 trials
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Recruiting·—·Phase 2·NCT06354140·45 enrolled
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05724329·24 enrolled
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT07353294·12 enrolled
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07031700·22 enrolled
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT07475026·198 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)